UY25300A1 - Composiciones conteniendo un antagonista alfa adrenérgico y un compuesto que eleva los niveles de cgmp para el tratamiento de la impotencia - Google Patents

Composiciones conteniendo un antagonista alfa adrenérgico y un compuesto que eleva los niveles de cgmp para el tratamiento de la impotencia

Info

Publication number
UY25300A1
UY25300A1 UY25300A UY25300A UY25300A1 UY 25300 A1 UY25300 A1 UY 25300A1 UY 25300 A UY25300 A UY 25300A UY 25300 A UY25300 A UY 25300A UY 25300 A1 UY25300 A1 UY 25300A1
Authority
UY
Uruguay
Prior art keywords
treatment
impotence
compound
raises
compositions containing
Prior art date
Application number
UY25300A
Other languages
English (en)
Inventor
Michael Grant Wyllie
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22090927&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY25300(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY25300A1 publication Critical patent/UY25300A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta invención se refiere al tratamiento de la disfunción eréctil con una combinación de un compuesto seleccionado entre antagonistas de los receptores a-adrenergicos, y un compuesto seleccionado entre los agentes que elevan los niveles de cgmp. se prefiere como elevador de cgmp pde al sildenafilo o una sal farmacéuticamente aceptable del mismo. También se incluyen composiciones y estuches que comprenden tales compuestos para el tratamiento de la impotencia.
UY25300A 1997-12-16 1998-12-14 Composiciones conteniendo un antagonista alfa adrenérgico y un compuesto que eleva los niveles de cgmp para el tratamiento de la impotencia UY25300A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6974197P 1997-12-16 1997-12-16

Publications (1)

Publication Number Publication Date
UY25300A1 true UY25300A1 (es) 2000-12-29

Family

ID=22090927

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25300A UY25300A1 (es) 1997-12-16 1998-12-14 Composiciones conteniendo un antagonista alfa adrenérgico y un compuesto que eleva los niveles de cgmp para el tratamiento de la impotencia

Country Status (37)

Country Link
EP (1) EP1037616B1 (es)
JP (2) JP2002508315A (es)
KR (1) KR20010033092A (es)
CN (1) CN1282248A (es)
AP (1) AP915A (es)
AR (1) AR016433A1 (es)
AT (1) ATE318602T1 (es)
AU (1) AU759825B2 (es)
BG (1) BG104528A (es)
BR (1) BR9813699A (es)
CA (1) CA2314993A1 (es)
CO (1) CO4810381A1 (es)
CZ (1) CZ20002199A3 (es)
DE (1) DE69833671T2 (es)
DZ (1) DZ2675A1 (es)
EA (1) EA200000526A1 (es)
ES (1) ES2258300T3 (es)
GT (1) GT199800177A (es)
HN (1) HN1998000174A (es)
HR (1) HRP20000407A2 (es)
HU (1) HUP0100705A3 (es)
IL (1) IL136515A0 (es)
IS (1) IS5504A (es)
MA (1) MA26586A1 (es)
NO (1) NO20003065L (es)
NZ (1) NZ504487A (es)
OA (1) OA11423A (es)
PA (1) PA8462801A1 (es)
PE (1) PE20000011A1 (es)
PL (1) PL341575A1 (es)
SK (1) SK8782000A3 (es)
TN (1) TNSN98227A1 (es)
TR (1) TR200001733T2 (es)
UY (1) UY25300A1 (es)
WO (1) WO1999030697A2 (es)
YU (1) YU33700A (es)
ZA (1) ZA9811507B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6469065B1 (en) 1996-02-02 2002-10-22 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist, compositions and methods of use
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
DE19844162A1 (de) * 1998-09-25 2000-03-30 Udo Dunzendorfer Medikamentenkombinationen zur Therapie der erektilen Dysfunktion
WO2000053148A2 (en) * 1999-03-08 2000-09-14 Merck & Co., Inc. Methods and compositions for treating erectile dysfunction
US7235625B2 (en) * 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
ES2435816T3 (es) * 1999-08-03 2013-12-23 Icos Corporation Formulación farmacéutica que comprende una Beta-carbolina y su uso para el tratamiento de la disfunción sexual
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
WO2002022127A1 (en) * 2000-09-13 2002-03-21 Isis Innovation Limited Use of phosphodiesterase inhibitors for the treatment of anorectal disorders
EP1333824B1 (en) * 2000-11-17 2005-09-07 Warner-Lambert Company LLC Treatment of sexual dysfunction with bombesin receptor antagonists
US20030114469A1 (en) * 2001-09-27 2003-06-19 Cohen David Saul Combinations
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
GB0225908D0 (en) * 2002-11-06 2002-12-11 Pfizer Ltd Treatment of female sexual dysfunction
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
US7291640B2 (en) 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
EP2218442A1 (en) 2005-11-09 2010-08-18 CombinatoRx, Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
US8293489B2 (en) 2007-01-31 2012-10-23 Henkin Robert I Methods for detection of biological substances
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
CN101781302B (zh) * 2009-05-31 2013-07-10 段波 一种磷酸二酯酶抑制剂和异黄酮形成的加成物及其应用
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
EP2903619B1 (en) 2012-10-05 2019-06-05 Robert I. Henkin Phosphodiesterase inhibitors for treating taste and smell disorders
CN106233141B (zh) 2014-02-18 2018-08-21 罗伯特·I·汉金 用于诊断和治疗味觉或嗅觉的损失和/或失真的方法和组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA878182B (en) * 1986-11-05 1988-05-02 Merrell Dow Pharmaceuticals Inc. Enhancement of prazosin
FR2649613B1 (fr) * 1989-07-11 1991-09-27 Virag Ronald Medicament vaso-actif
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
DE69105040T2 (de) * 1990-05-31 1995-03-23 Pfizer, Inc., New York, N.Y. Arzneimittel gegen Impotenz.
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB9523752D0 (en) * 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations

Also Published As

Publication number Publication date
HRP20000407A2 (en) 2000-10-31
CZ20002199A3 (cs) 2001-10-17
BR9813699A (pt) 2000-10-10
GT199800177A (es) 2000-05-02
WO1999030697A2 (en) 1999-06-24
TR200001733T2 (tr) 2000-11-21
JP2002508315A (ja) 2002-03-19
HUP0100705A2 (hu) 2001-08-28
CN1282248A (zh) 2001-01-31
DE69833671T2 (de) 2006-11-30
HUP0100705A3 (en) 2001-12-28
ES2258300T3 (es) 2006-08-16
PA8462801A1 (es) 2000-05-24
IS5504A (is) 2000-05-19
EA200000526A1 (ru) 2000-12-25
DE69833671D1 (de) 2006-04-27
IL136515A0 (en) 2001-06-14
SK8782000A3 (en) 2002-03-05
NO20003065D0 (no) 2000-06-15
AU9455898A (en) 1999-07-05
AR016433A1 (es) 2001-07-04
DZ2675A1 (fr) 2003-03-29
PL341575A1 (en) 2001-04-23
NO20003065L (no) 2000-08-15
YU33700A (sh) 2004-05-12
WO1999030697A3 (en) 1999-08-26
JP2007332156A (ja) 2007-12-27
KR20010033092A (ko) 2001-04-25
CO4810381A1 (es) 1999-06-30
EP1037616A2 (en) 2000-09-27
MA26586A1 (fr) 2004-12-20
TNSN98227A1 (fr) 2005-03-15
EP1037616B1 (en) 2006-03-01
ZA9811507B (en) 2000-06-19
BG104528A (en) 2001-02-28
HN1998000174A (es) 1999-01-08
NZ504487A (en) 2002-11-26
PE20000011A1 (es) 2000-01-18
ATE318602T1 (de) 2006-03-15
OA11423A (en) 2004-04-21
AP9801414A0 (en) 1998-12-31
CA2314993A1 (en) 1999-06-24
AP915A (en) 2000-12-18
AU759825B2 (en) 2003-05-01

Similar Documents

Publication Publication Date Title
UY25300A1 (es) Composiciones conteniendo un antagonista alfa adrenérgico y un compuesto que eleva los niveles de cgmp para el tratamiento de la impotencia
ES2159839T3 (es) Derivados del propano, su preparacion y su uso.
ES2175350T3 (es) Compuestos triciclicos que tienen afinidad de union a receptores de melatonina, su produccion y uso.
CL2018002358A1 (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
PE20020366A1 (es) Derivados de piperazina como ligandos del receptor 5ht2
PA8546601A1 (es) Nuevos derivados de indol con afinidad por el receptor 5-ht6
ES2161231T3 (es) Compuestos heterociclicos como antagonistas de bradiquinina.
PE20060531A1 (es) Derivados de piridazin-3-(2h)-ona como inhibidores de la fosfodiesterasa 4
PA8547901A1 (es) Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6
UY27943A1 (es) Composiciones y mctodos para tratar el crncer usando inmunoconjugados de anticuerpo para cd44 citotnxicos y agentes quimioterapcuticos
UY28026A1 (es) 4-piperazinilbencenosulfonilindoles y usos de los mismos.
ECSP055525A (es) Inhibidores de cinasas de tirosina
AR049646A1 (es) Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
CR7235A (es) Inhibidores beta- amino tetrahidroimidazol (1,2-a) pirazinas y tetrahidrotrioazolo (4,3-a) pirazinas como depetidil peptidasa para el tratamiento o prevencion de la diabetes
UY26482A1 (es) Bifenil sulfonamidas como antagonistas de receptores de angiotensina endotelina duales
ES2162933T3 (es) Compuestos utiles como agentes antiproliferativos e inhibidores del enzima glicinamida ribonucleotido formilo transferasa (garft).
UY26071A1 (es) Inhibidores fusionados de piridopiridazina de fosfodiesterasa de cgmp
UY27232A1 (es) Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientos
EP1090644A3 (en) Combination effective for the treatment of impotence comprising a potassium-channel-opener and a cGMP elevator
UY27998A1 (es) Piperazinas sustituidas sustituidas heterocíclicas para el tratamiento de la esquizofrenia
ECSP982789A (es) Combinacion eficaz para el tratamiento de la impotencia
ES2156889T3 (es) Compuestos biciclicos antagonistas de receptores de aminoacidos excitativos.
PE20040906A1 (es) Derivados morfolinicos como agonistas de dopamina
PE20040868A1 (es) Nueva combinacion de inhibidor de fosfodiesterasa de tipo 5 (pde5) y antagonista del receptor de angiotensina ii
AU3324201A (en) Tosylproline analogs as thymidylate synthase inhibitors

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20041111